InhA: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 39: Line 39:


=InhA and Thioamide Drugs=
=InhA and Thioamide Drugs=
<Structure load='2h9i' size='275' frame='true' align='left' caption='Momomeric subunit of InhA with bound EAD' scene='Sandbox_Reserved_321/Structural_progresion/1' />
[[Image:ETH, EAD, PTH, P1H structures.png|thumb|left|upright=1.5|alt=ETH, EAD, PTH, and P1H.|Fig 3: Structures of ETH, EAD, PTH, and P1H]]
 
[[Image:ETH, EAD, PTH, P1H structures.png|thumb|right|upright=1.5|alt=ETH, EAD, PTH, and P1H.|Fig 3: Structures of ETH, EAD, PTH, and P1H]]


The primary target of the thioamide drugs PTH and ETH have been shown to be InhA <scene name='Sandbox_Reserved_321/Structural_progresion/1'>(go to original scene)</scene> in both genetic and molecular experiments<ref name ="mech of thioamide drug action"/>. Both PTH and ETH require activation by various cellular componets to form the NAD adduct that acts to inhibit InhA, and therefore connot be studied in [http://en.wikipedia.org/wiki/In_vitro in vitro]<ref name ="mech of thioamide drug action"/>.  The exacct mechanism of their activation is still under speculation, however a flavin monooxygenase (EthA) has been shown to participate in ETH and PTH activation<ref name ="mech of thioamide drug action"/>.  In fact, strains of ''M. tuberculosis'' that have mutations in the gene which express EthA exhibit resistance to thioamide drugs<ref name ="mech of thioamide drug action"/>.  Currently studies are being carried out to determine other methods of treatment for mycobaterial infections that dont require activation by cellular constituents, due to the incerease of drug resistant cases world wide.
The primary target of the thioamide drugs PTH and ETH have been shown to be InhA <scene name='Sandbox_Reserved_321/Structural_progresion/1'>(go to original scene)</scene> in both genetic and molecular experiments<ref name ="mech of thioamide drug action"/>. Both PTH and ETH require activation by various cellular componets to form the NAD adduct that acts to inhibit InhA, and therefore connot be studied in [http://en.wikipedia.org/wiki/In_vitro in vitro]<ref name ="mech of thioamide drug action"/>.  The exacct mechanism of their activation is still under speculation, however a flavin monooxygenase (EthA) has been shown to participate in ETH and PTH activation<ref name ="mech of thioamide drug action"/>.  In fact, strains of ''M. tuberculosis'' that have mutations in the gene which express EthA exhibit resistance to thioamide drugs<ref name ="mech of thioamide drug action"/>.  Currently studies are being carried out to determine other methods of treatment for mycobaterial infections that dont require activation by cellular constituents, due to the incerease of drug resistant cases world wide.
Line 76: Line 74:


InhA can be further classified into the acyl carrier protein family(ACP's). These proteins generally all function in the transport of substrates in a myriad of pathways, such as: the synthesis of polypeptides and fatty acids<ref name ="Acyl Carrier Proteins">PMID:17012233</ref>.   
InhA can be further classified into the acyl carrier protein family(ACP's). These proteins generally all function in the transport of substrates in a myriad of pathways, such as: the synthesis of polypeptides and fatty acids<ref name ="Acyl Carrier Proteins">PMID:17012233</ref>.   
</StructureSection>
__NOTOC__


''3D structures of ACP family''
''3D structures of ACP family''

Revision as of 07:48, 21 August 2013

Drag the structure with the mouse to rotate


3D structures of ACP family

1bxk

Additional Resources


References

Proteopedia Page Contributors and Editors (what is this?)

Kelly Hrywkiw, Alexander Berchansky, Michal Harel